- Home
- NSTS vs IMA Comparison
NSTS vs IMA Comparison
Compare NSTS & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NSTS | IMA |
|---|---|---|
| Founded | 1921 | 2019 |
| Country | United States | United States |
| Employees | N/A | 15 |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.8M | 65.3M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | NSTS | IMA |
|---|---|---|
| Price | $11.70 | $4.51 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 6.8K | ★ 35.2K |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $252,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.73 | $3.94 |
| 52 Week High | $13.06 | $17.50 |
Technical Indicators
Market Signals| Indicator | NSTS | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 47.23 | 32.55 |
| Support Level | $11.48 | $3.94 |
| Resistance Level | $12.38 | $7.17 |
| Average True Range (ATR) | 0.25 | 0.39 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 49.32 | 39.39 |
Price Performance
Historical ComparisonAbout NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.